
Browsing restrictions can be lifted for a fee.
## NVO PE Stream Chart Analysis As of the latest data point (mid-March 2026), NVO's monthly average price stands at approximately **$37.45**, which has fallen **below the lowest PE boundary of 1.6 times** (priced at ~$37.44). This places the stock firmly in the **Undervalued** zone — the most deeply discounted valuation tier on the PE stream chart. The current price is well beneath the 2.7 times boundary (~$62.02), the 3.8 times boundary (~$86.59), the 4.8 times boundary (~$111.40), the 5.9 times boundary (~$135.98), and the 7.0 times boundary (~$160.55). This extreme positioning signals that NVO is trading at historically compressed valuations relative to its earnings, representing a significant departure from where the stock was priced just 12–18 months ago. Historically, NVO's valuation trajectory tells a dramatic story of expansion followed by sharp contraction. From early 2021 through mid-2024, the stock climbed steadily through the PE bands — beginning in the **Fair** zone (between 3.8 times and 4.8 times) and progressively advancing into the **Watch** and **Overvalued** zones. The stock reached its peak valuation around mid-2024, when prices briefly approached or touched the **7.0 times (Warning)** boundary near ~$138–$139, reflecting peak investor enthusiasm — likely tied to the GLP-1/obesity drug boom. From late 2024 onward, however, the price began a sustained and steep decline, retreating through each PE band in succession. By late 2025 and into early 2026, the stock broke below the 2.7 times **Value** zone and ultimately collapsed beneath the 1.6 times **Undervalued** threshold. Notably, the PE stream bands themselves have continued to trend upward throughout this period, suggesting that the company's underlying earnings have remained on a growth trajectory — making the current price compression even more pronounced. This divergence between rising PE boundaries and a falling stock price indicates a significant valuation de-rating, warranting close attention from investors evaluating long-term entry opportunities.